AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24642082 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompts announcing new animated videos
Number of subjects: 1124
Study 24642082 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompts about games related to (non-)smoking
Number of subjects: 1124
Study 24642082 — intervention group
Group type: EXPERIMENTAL
Intervention: Low socioeconomic status (SES) children in the prompt group
Number of subjects: 1124
Study 22356584 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole (16 mg)
Number of subjects: 0
Study 22356584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20307393 — intervention group
Group type: EXPERIMENTAL
Intervention: Few Touch application (mobile phone-based self-management tool)
Number of subjects: 12
Study 17685733 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM) program on antipsychotic drug choice
Number of subjects: 107
Study 17685733 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 107
Study 15849749 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational material provided 3 times yearly
Number of subjects: 1232
Study 15849749 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and 800 ml free broad spectrum sunscreens with SPF 25 provided yearly
Number of subjects: 1232
Study 15849749 — intervention group
Group type: COMPARATOR
Intervention: Parents informed on study purpose and sun protection measures only at an initial educational meeting
Number of subjects: 1232
Study 12109619 — intervention group
Group type: EXPERIMENTAL
Intervention: OGTT (Oral Glucose Tolerance Test) at baseline and 3-year follow-up
Number of subjects: 14
Study 12109619 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of peripheral insulin sensitivity using HOMA index and a novel index from OGTT
Number of subjects: 14
Study 12109619 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up measurements of fasting glycemia
Number of subjects: 14
Study 9788383 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol gut lavage taken the same morning as colonoscopy (Group 1)
Number of subjects: 317
Study 9788383 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol gut lavage taken the afternoon before colonoscopy (Group 2)
Number of subjects: 317
Study 7624100 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 1173
Study 7624100 — intervention group
Group type: COMPARATOR
Intervention: Other antibiotics or non-treated controls
Number of subjects: 1173
Study 2794250 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar electrode pair at different stimulus currents
Number of subjects: 1
Study 2794250 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bipolar electrode pairs with different spatial extents (1.5 mm and 4.5 mm)
Number of subjects: 1
Study 2794250 — intervention group
Group type: EXPERIMENTAL
Intervention: Two loudness balanced bipolar masker electrode pairs activated within a stimulus period
Number of subjects: 1
Study 208462 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole, 50 mg three times daily for 3 days
Number of subjects: 109
Study 208462 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 109
Study 208462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 31494945 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial colloid priming group (AC group, n = 33)
Number of subjects: 65
Study 31494945 — intervention group
Group type: COMPARATOR
Intervention: Artificial colloid combined with human serum albumin priming group (ACA group, n = 32)
Number of subjects: 65
Study 30877051 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment‐Based Family Therapy (ABFT)
Number of subjects: 0
Study 30877051 — intervention group
Group type: COMPARATOR
Intervention: Family‐Enhanced NonDirective Supportive Therapy (FE‐NST)
Number of subjects: 0
Study 29147888 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental presence/absence (PPA) technique
Number of subjects: 61
Study 29147888 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-pharmacological techniques)
Number of subjects: 61
Study 24480912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 23548250 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet-delivered acceptance and commitment therapy (ACT) for 7 weeks
Number of subjects: 76
Study 23548250 — intervention group
Group type: COMPARATOR
Intervention: Moderated online discussion forum (Control)
Number of subjects: 76
Study 23548250 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet-delivered acceptance and commitment therapy (ACT)
Number of subjects: 76
Study 21878168 — intervention group
Group type: EXPERIMENTAL
Intervention: ITBVI group (17 patients)
Number of subjects: 33
Study 21878168 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 patients)
Number of subjects: 33
Study 18952810 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated morphological awareness intervention
Number of subjects: 16
Study 18952810 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 16775680 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs (paracetamol or parecoxib/valdecoxib) with piritramid
Number of subjects: 180
Study 16775680 — intervention group
Group type: COMPARATOR
Intervention: Control group (piritramid only)
Number of subjects: 180
Study 12841663 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation with 5-fluorouracil (350 mg/m2/day) and folinic acid (10 mg/m2) administered as intravenous bolus on days 1-5 and 29-33 of radiotherapy, followed by surgery after 4-6 weeks.
Number of subjects: 27
Study 11036135 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincisional bupivacaine
Number of subjects: 74
Study 11036135 — intervention group
Group type: COMPARATOR
Intervention: Postincisional bupivacaine
Number of subjects: 74
Study 10369641 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletonizing technique (Group A)
Number of subjects: 20
Study 10369641 — intervention group
Group type: COMPARATOR
Intervention: Classical pedicle preparation technique (Group B)
Number of subjects: 20
Study 10369641 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine soaking
Number of subjects: 20
Study 10369641 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass flow
Number of subjects: 20
Study 10369641 — intervention group
Group type: EXPERIMENTAL
Intervention: Transit-time flow measurement
Number of subjects: 20
Study 1313116 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin
Number of subjects: 182
Study 1313116 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 182
Study 2939794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 100 mg
Number of subjects: 9
Study 2939794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 150 mg
Number of subjects: 9
Study 2939794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 200 mg
Number of subjects: 9
Study 2939794 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 9
Study 29599611 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir plus asunaprevir (DUAL) - daclatasvir 60 mg once daily and asunaprevir 100 mg twice daily for 24 weeks
Number of subjects: 207
Study 29599611 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 weeks) followed by DUAL treatment
Number of subjects: 207
Study 29599611 — intervention group
Group type: EXPERIMENTAL
Intervention: DUAL treatment during double-blind phase
Number of subjects: 207
Study 29599611 — intervention group
Group type: EXPERIMENTAL
Intervention: DUAL treatment during 24 weeks (combined arms)
Number of subjects: 207
Study 26913649 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K deficiency (PIVKA-II > 2 μg/L)
Number of subjects: 500
Study 25047001 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary delivery of the anterior shoulder
Number of subjects: 650
Study 25047001 — intervention group
Group type: COMPARATOR
Intervention: Primary delivery of the posterior shoulder
Number of subjects: 650
Study 22230058 — intervention group
Group type: EXPERIMENTAL
Intervention: bFGF eye drops
Number of subjects: 100
Study 22230058 — intervention group
Group type: COMPARATOR
Intervention: Control (saline drops)
Number of subjects: 100
Study 20427682 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic treatment strategy targeting A1C <6.0%
Number of subjects: 10251
Study 20427682 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemic treatment strategy targeting A1C 7.0‐7.9%
Number of subjects: 10251
Study 18771374 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib, 120 mg/day for 7 days
Number of subjects: 20
Study 18771374 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 20
Study 15559483 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% icodextrin/1.36% glucose combination dialysate
Number of subjects: 8
Study 15559483 — intervention group
Group type: COMPARATOR
Intervention: Control: 7.5% icodextrin alone
Number of subjects: 8
Study 11516109 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine (FAMP)
Number of subjects: 92
Study 11516109 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, doxorubicin and prednisone (CAP)
Number of subjects: 92
Study 11516109 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-adjusted survival analysis (Q-TWiST)
Number of subjects: 92
Study 9257067 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin/vinblastine with hydrazine sulfate (HS)
Number of subjects: 291
Study 9257067 — intervention group
Group type: COMPARATOR
Intervention: cisplatin/vinblastine with placebo
Number of subjects: 291
Study 8388949 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (early treatment group, n = 10)
Number of subjects: 21
Study 8388949 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (late treatment group, n = 11)
Number of subjects: 21
Study 3481361 — intervention group
Group type: EXPERIMENTAL
Intervention: Incision and drainage with subsequent oral antibiotics and oral hydration
Number of subjects: 27
Study 3481361 — intervention group
Group type: COMPARATOR
Intervention: Incision and drainage with subsequent hospitalization for intravenous antibiotics and hydration
Number of subjects: 27
Study 29782187 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 3,800 IU daily
Number of subjects: 13
Study 29782187 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 400 IU daily
Number of subjects: 13
Study 27836017 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (watched a video, received online information, tracked intake using a mobile application for 12 weeks)
Number of subjects: 90
Study 27836017 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 90
Study 27836017 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 23945164 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 60
Study 23945164 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 60
Study 23945164 — intervention group
Group type: COMPARATOR
Intervention: Manual needle placement
Number of subjects: 60
Study 22929243 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolation plus de‐epithelialization group
Number of subjects: 60
Study 22929243 — intervention group
Group type: COMPARATOR
Intervention: Isolation group
Number of subjects: 60
Study 20688403 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implants (CIs)
Number of subjects: 63
Study 20688403 — intervention group
Group type: COMPARATOR
Intervention: Normal hearing (NH)
Number of subjects: 63
Study 18782876 — intervention group
Group type: EXPERIMENTAL
Intervention: High-morning hydrocortisone (HC) dose (50% of daily dose in the morning)
Number of subjects: 15
Study 18782876 — intervention group
Group type: COMPARATOR
Intervention: High-evening hydrocortisone (HC) dose (50% of daily dose in the evening)
Number of subjects: 15
Study 16884553 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil-based anaesthesia
Number of subjects: 50
Study 16884553 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-fentanyl-based anaesthesia
Number of subjects: 50
Study 14654485 — intervention group
Group type: EXPERIMENTAL
Intervention: QuickSeal system (gelatin sponge closure device)
Number of subjects: 141
Study 14654485 — intervention group
Group type: COMPARATOR
Intervention: Manual compression (control)
Number of subjects: 141
Study 11107790 — intervention group
Group type: EXPERIMENTAL
Intervention: Phagocytic activity of PMN
Number of subjects: 0
Study 11107790 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 0
Study 11107790 — intervention group
Group type: EXPERIMENTAL
Intervention: Phagocytic activity connected with intracellular oxygen metabolism
Number of subjects: 0
Study 11107790 — intervention group
Group type: COMPARATOR
Intervention: PMN activity tests (phagocytosis, NBT test)
Number of subjects: 0
Study 8800215 — intervention group
Group type: EXPERIMENTAL
Intervention: Handrim with an oval 25 by 30 mm diameter (LR)
Number of subjects: 6
Study 8800215 — intervention group
Group type: COMPARATOR
Intervention: Handrim with an 18 mm diameter (SR)
Number of subjects: 6
Study 1622907 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg aspirin daily
Number of subjects: 46
Study 1622907 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 46
Study 6370703 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (T) 5.0 mg/kg
Number of subjects: 8
Study 6370703 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline (E) 1.5 mg/kg
Number of subjects: 8
Study 6370703 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) 0.9% saline
Number of subjects: 8
Study 30783648 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (cTBS) over the left posterior parietal cortex, applied in either eight or 16 trains.
Number of subjects: 60
Study 30783648 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (cTBS) over the left posterior parietal cortex.
Number of subjects: 60
Study 30783648 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without neglect).
Number of subjects: 60
Study 29849487 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise (n = 49)
Number of subjects: 125
Study 29849487 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy (n = 43)
Number of subjects: 125
Study 29849487 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 125
Study 27470121 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (N = 103)
Number of subjects: 219
Study 27470121 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 116)
Number of subjects: 219
Study 24272364 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology triage at atypical squamous cells of undetermined significance threshold
Number of subjects: 0
Study 24272364 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection with acetic acid (VIA) triage
Number of subjects: 0
Study 22976384 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality balance training (VRBT) for 30 min a day, 3 times a week for 6 weeks
Number of subjects: 22
Study 22976384 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard rehabilitation program)
Number of subjects: 22
Study 19282749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (PP)
Number of subjects: 24
Study 19282749 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile perfusion (NP)
Number of subjects: 24
Study 17768472 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 10% zinc sulphate solution
Number of subjects: 100
Study 17768472 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% zinc sulphate solution
Number of subjects: 100
Study 17768472 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 100
Study 15514406 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram, 10-40 mg/day
Number of subjects: 174
Study 15514406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 15514406 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 174
Study 11580079 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg/day for 2 years and then 10 mg/day for 1 year)
Number of subjects: 2027
Study 9694049 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with factor V Leiden mutation
Number of subjects: 34
Study 9694049 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without factor V Leiden mutation
Number of subjects: 34
Study 9694049 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 34
Study 7633170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovum pickup at 36 hr after hCG injection (group B)
Number of subjects: 90
Study 7633170 — intervention group
Group type: COMPARATOR
Intervention: Ovum pickup at 35 hr after hCG injection (group A)
Number of subjects: 90
Study 7633170 — intervention group
Group type: COMPARATOR
Intervention: Ovum pickup at 37 hr after hCG injection (group C)
Number of subjects: 90
Study 3129780 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin for 5 days
Number of subjects: 216
Study 3129780 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin for 10 days
Number of subjects: 216
Study 3129780 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil for 10 days
Number of subjects: 216
Study 29183910 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensifying treatments to three oral agents or insulin regimens
Number of subjects: 5813
Study 29183910 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin alone use
Number of subjects: 5813
Study 29183910 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment satisfaction (patient-reported)
Number of subjects: 5813
Study 29183910 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit of Diabetes‐Dependent Quality of Life (ADDQoL)
Number of subjects: 5813
Study 29183910 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia Fear Survey‐II worry subscale
Number of subjects: 5813
Study 29183910 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 5813
Study 26414990 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran (100 mg/d)
Number of subjects: 19
Study 26414990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 24210533 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 165
Study 24210533 — intervention group
Group type: COMPARATOR
Intervention: Brief advice (BA)
Number of subjects: 165
Study 24210533 — intervention group
Group type: COMPARATOR
Intervention: Brief advice (BA) with nicotine replacement (NRT)
Number of subjects: 165
Study 24210533 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) with nicotine replacement (NRT)
Number of subjects: 165
Study 23945386 — intervention group
Group type: EXPERIMENTAL
Intervention: Overexpression of WT1 in H1568 and H1650 NSCLC cell lines
Number of subjects: 159
Study 23945386 — intervention group
Group type: EXPERIMENTAL
Intervention: Knockdown of WT1 in H1568 and H1650 NSCLC cell lines
Number of subjects: 159
Study 23945386 — intervention group
Group type: EXPERIMENTAL
Intervention: WT1 mRNA levels
Number of subjects: 159
Study 23945386 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical correlation of WT1 expression
Number of subjects: 159
Study 20843375 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral pH, low GDP dialysis solution (Balance)
Number of subjects: 185
Study 20843375 — intervention group
Group type: COMPARATOR
Intervention: Conventional dialysis solution (Stay.safe)
Number of subjects: 185
Study 18993156 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week group-based aerobic high-intensity interval training model twice weekly for 65 to 80 minutes/day (n = 40)
Number of subjects: 80
Study 18993156 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group, n = 40)
Number of subjects: 80
Study 17132385 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised advice and a tapering off schedule with biweekly follow‐up visits (n = 73)
Number of subjects: 139
Study 17132385 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical practice (n = 66)
Number of subjects: 139
Study 12932090 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-day course of artesunate (Group A5)
Number of subjects: 801
Study 12932090 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven-day course of artesunate (Group A7)
Number of subjects: 801
Study 12932090 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-day course of artesunate plus a 14-day course of high-dose primaquine (0.6 mg/kg, maximum dose = 30 mg) (Group A5 + P)
Number of subjects: 801
Study 12932090 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven-day course of artesunate plus a 14-day course of high-dose primaquine (Group A7 + P)
Number of subjects: 801
Study 12932090 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose primaquine (0.6 mg/kg of base a day)
Number of subjects: 801
Study 14747668 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet providing an ample protein intake (1.67 g. kg fat-free mass(‐1). d(‐1))
Number of subjects: 14
Study 14747668 — intervention group
Group type: COMPARATOR
Intervention: Diet approximating the mean minimum adult protein requirement (0.71 g. kg fat-free mass(‐1). d(‐1))
Number of subjects: 14
Study 10203120 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated Presence
Number of subjects: 54
Study 10203120 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 54
Study 10203120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 7760775 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental mercury exposure (mean urinary Hg = 36 micrograms/l)
Number of subjects: 39
Study 7760775 — intervention group
Group type: COMPARATOR
Intervention: Unexposed dentists (control group)
Number of subjects: 39
Study 1970265 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg, single oral dose)
Number of subjects: 0
Study 1970265 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0